Literature DB >> 31960985

Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis.

Andrew M Moon1, Yue Jiang2, Shari S Rogal3, Elliot B Tapper4,5, Sarah R Lieber1, A Sidney Barritt1.   

Abstract

BACKGROUND: Opioids are often prescribed for pain in cirrhosis and may increase the risk of hepatic encephalopathy (HE). AIM: To assess the association between opioids and HE in patients with well-compensated cirrhosis.
METHODS: We used the IQVIA PharMetrics (Durham, NC) database to identify patients aged 18-64 years with cirrhosis. We excluded patients with any decompensation event from 1 year before cirrhosis diagnosis to 6 months after cirrhosis diagnosis. Over the 6 months after cirrhosis diagnosis, we determined the duration of continuous opioid use and classified use into short term (1-89 days) and chronic (90-180 days). We assessed whether patients developed HE over the subsequent year (ie 6-18 months after cirrhosis diagnosis). We used a landmark analysis and performed multivariable Cox proportional hazards regression to assess associations between opioid use and HE, adjusting for relevant confounders.
RESULTS: The cohort included 6451 patients with compensated cirrhosis, of whom 23.3% and 4.7% had short-term and chronic opioid prescriptions respectively. Over the subsequent year, HE occurred in 6.3% patients with chronic opioid prescriptions, 5.0% with short-term opioid prescriptions and 3.3% with no opioid prescriptions. In the multivariable model, an increased risk of HE was observed with short-term (adjusted hazard ratio, HR 1.44, 95% CI 1.07-1.94) and chronic opioid prescriptions (adjusted HR 1.83, 95% CI 1.07-3.12) compared to no opioid prescriptions.
CONCLUSION: In this national cohort of privately insured patients with cirrhosis, opioid prescriptions were associated with the risk of incident HE. Opioid use should be minimised in those with cirrhosis and, when required, limited to short duration.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31960985      PMCID: PMC7047528          DOI: 10.1111/apt.15639

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  37 in total

Review 1.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Authors:  Gennaro D'Amico; Guadalupe Garcia-Tsao; Luigi Pagliaro
Journal:  J Hepatol       Date:  2005-11-09       Impact factor: 25.083

Review 2.  Exercise for osteoarthritis of the hip.

Authors:  Marlene Fransen; Sara McConnell; Gabriela Hernandez-Molina; Stephan Reichenbach
Journal:  Cochrane Database Syst Rev       Date:  2014-04-22

Review 3.  Exercise for osteoarthritis of the knee.

Authors:  Marlene Fransen; Sara McConnell; Alison R Harmer; Martin Van der Esch; Milena Simic; Kim L Bennell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

4.  Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Richard K Sterling; Arun J Sanyal; Muhammad Siddiqui; Scott Matherly; Velimir Luketic; R Todd Stravitz; Michael Fuchs; Leroy R Thacker; HoChong Gilles; Melanie B White; Ariel Unser; James Hovermale; Edith Gavis; Nicole A Noble; James B Wade
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-17       Impact factor: 11.382

5.  Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.

Authors:  D A Stempel; J Mauskopf; T McLaughlin; C Yazdani; R H Stanford
Journal:  Respir Med       Date:  2001-03       Impact factor: 3.415

6.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

Review 7.  Exercise for treating fibromyalgia syndrome.

Authors:  A J Busch; K A R Barber; T J Overend; P M J Peloso; C L Schachter
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

8.  Chronic pain among liver transplant candidates.

Authors:  Alok Madan; Kelly S Barth; Wendy E Balliet; Melba A Hernandez-Tejada; Jeffrey J Borckardt; Robert Malcolm; Ira Willner; David Koch; Adrian Reuben
Journal:  Prog Transplant       Date:  2012-12       Impact factor: 1.187

9.  The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study.

Authors:  K M Fleming; G P Aithal; T R Card; J West
Journal:  Aliment Pharmacol Ther       Date:  2010-10-04       Impact factor: 8.171

10.  Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease.

Authors:  Monica A Konerman; Mary Rogers; Brooke Kenney; Amit G Singal; Elliot Tapper; Pratima Sharma; Sameer Saini; Brahmajee Nallamothu; Akbar Waljee
Journal:  BMJ Open Gastroenterol       Date:  2019-04-14
View more
  11 in total

1.  Integrated Care of Alcohol-Related Liver Disease.

Authors:  Gerald S Winder; Anne C Fernandez; Jessica L Mellinger
Journal:  J Clin Exp Hepatol       Date:  2022-01-31

Review 2.  Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.

Authors:  Jeremy Louissaint; Sasha Deutsch-Link; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2022-08       Impact factor: 13.576

Review 3.  Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease.

Authors:  Rachel L Bachrach; Shari S Rogal
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-05-23

4.  Using Intervention Mapping to Develop a Novel Pain Self-Management Intervention for People with Cirrhosis.

Authors:  Shari S Rogal; Matthew J Chinman; William DeMonte; Sandra Gibson; Stephanie Hoyt-Trapp; Gloria J Klima; Naudia L Jonassaint; Jane M Liebschutz; Kevin L Kraemer; Jessica Merlin
Journal:  Dig Dis Sci       Date:  2022-02-11       Impact factor: 3.487

5.  Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.

Authors:  Shari Rogal; Ada Youk; Olufunso Agbalajobi; Hongwei Zhang; Walid Gellad; Michael J Fine; Pamela Belperio; Timothy Morgan; Chester B Good; Kevin Kraemer
Journal:  Am J Gastroenterol       Date:  2021-07-01       Impact factor: 12.045

Review 6.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

7.  In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge.

Authors:  Andrew M Moon; Yue Jiang; Shari S Rogal; Jasper Becker; A Sidney Barritt
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

8.  Short-Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis.

Authors:  Mitchell R McGill; Laura P James; Sandra S McCullough; Jeffery H Moran; Samuel E Mathews; Eric C Peterson; Davis P Fleming; Morgan E Tripod; Joel H Vazquez; Stefanie Kennon-McGill; Horace J Spencer; Jonathan A Dranoff
Journal:  Hepatol Commun       Date:  2021-08-25

9.  Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action.

Authors:  Olufunso M Agbalajobi; Theresa Gmelin; Andrew M Moon; Wheytnie Alexandre; Grace Zhang; Walid F Gellad; Naudia Jonassaint; Shari S Rogal
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.240

10.  Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease.

Authors:  Andrew M Moon; Stephanie E Watkins; Anna S Lok; Roberto J Firpi-Morell; Huy Ngoc Trinh; Justin T Kupec; Cheryl Schoen; Brent A Neuschwander-Tetri; A Sidney Barritt
Journal:  Dig Dis       Date:  2020-08-24       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.